| NCT07104500 | VK2735 for Weight Management Phase 3 | RECRUITING | PHASE3 | 2025-06-23 | 2027-08-01 | 2027-07-01 |
| NCT07104383 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | RECRUITING | PHASE3 | 2025-06-23 | 2027-08-01 | 2027-07-01 |
| NCT06828055 | VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | COMPLETED | PHASE2 | 2024-12-18 | 2025-08-15 | 2025-06-24 |
| NCT06068946 | VK2735 for Weight Management Phase 2 | COMPLETED | PHASE2 | 2023-08-31 | 2024-04-02 | 2024-02-27 |
| NCT05203237 | Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | COMPLETED | PHASE1 | 2021-12-14 | 2024-12-03 | 2024-11-04 |
| NCT04973657 | A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN | COMPLETED | PHASE1 | 2021-06-22 | 2024-11-08 | 2024-10-09 |
| NCT04173065 | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH | COMPLETED | PHASE2 | 2019-11-15 | 2024-01-26 | 2023-05-15 |
| NCT02927184 | Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease | COMPLETED | PHASE2 | 2016-09-28 | 2019-03-26 | 2019-03-26 |
| NCT02578095 | Acute Hip Fracture Study in Patients 65 Years or Greater | COMPLETED | PHASE2 | 2015-10-30 | 2018-03 | 2017-11-15 |